Stenting: Dynamic growth continues

Paris, France - The explosive growth in demand for drug eluting stents has shaped a market worth more than six billion euros annually.

According to figures published at EuroPCR, the annual European Paris Course of Revascularisation, some 2.5 million percutaneous coronary interventions (PCIs) will be performed globally this year - and 75% of these procedures will employ drug eluting stents (DES) - remarkable statistics for a medical technology that is under five years old.

At the meeting, Boston Scientific Corporation announced that it had received indication extensions to the European CE mark for its Taxus Liberté paclitaxel-eluting coronary stent system for use in some of the most challenging coronary procedures, including re-stenotic lesions and total occlusions in patients with coronary artery disease. These three new indications account for more than 20% of all coronary interventions.

Boston Scientific also announced funding for a new EU medical training facility - The Institute for Therapy Advancement - that will open in Brussels, Belgium, in early 2007. The company has several new pipeline offerings including the platinum alloy Taxus Barracuda stent, which has narrower struts for greater conformability, and the AST Petal stent platform for use in bifurcated vessels. The latter is designed to expand into the side branch, permitting blood to flow into both branches of the bifurcation and providing support at the branch.

01.07.2006

Read all latest stories

Related articles

Photo

Article •

Professional advice on devices testing and approval

BEO MedConsulting BERLIN GmbH, founded in 2000 and headquartered in Berlin since 2005, advises manufacturers on all issues concerning testing and approval of medical devices.

Photo

Article •

Met at KIMES

During KIMES, Karoline Laarmann (European Hospital) met with Joong-Ho Lee, Senior Executive Vice President of the ultrasound systems manufacturer MEDISON, the Korean firm that entered the ultrasound…

Photo

Article •

Toshiba invits experts to discuss the advantages of state-of-the-art technology

Toshiba's pre-opening ECR event on Wednesday evening attracted around 120 radiological experts who wanted to learn more about the company's technology in daily practice. Toshiba invited several…

Related products

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Canon – Alphenix Core

Single Plane

Canon – Alphenix Core

Canon Medical Systems Europe B.V.
CliniSys – Anatomical Pathology Laboratory

Information Technology

CliniSys – Anatomical Pathology Laboratory

CliniSys Deutschland GmbH
CliniSys – Clinical Laboratory

LIS / Middleware / POCT

CliniSys – Clinical Laboratory

CliniSys Deutschland GmbH
CliniSys – Genetics Laboratory

LIS / Middleware / POCT

CliniSys – Genetics Laboratory

CliniSys Deutschland GmbH
CliniSys – Order & Results Management

LIS / Middleware / POCT

CliniSys – Order & Results Management

CliniSys Deutschland GmbH
Subscribe to Newsletter